Expand PSIL Menu
PSIL MENU

PSIL ETF Profile


Family: Advisor Shares
Name: AdvisorShares Psychedelics ETF
Inception Date: 15-Sep-2021
Termination Date:
Investment Objective: The Fund is an actively managed exchange-traded fund ( ETF ) that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in (i) securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and (ii) derivatives that have economic characteristics similar to such securities. The Fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The Fund invests in exchange-listed equity securities, including common and preferred stock of U.S. and foreign mid, small and micro-capitalization companies, and in total return swaps intended to provide exposure to such companies.
Prospectus
Top 10 Holdings
ATAIBECKLEY INC ATAI 10.6600%
Definium Therapeutics Inc DFTX 8.7400%
COMPASS PATHWAYS PLC CMPS 8.6300%
SUPERNUS PHARMACEUTICALS INC SUPN 7.3100%
RELMADA THERAPEUTICS INC RLMD 6.6300%
GH RESEARCH PLC GHRS 6.2800%
ALKERMES PLC ALKS 5.9900%
NEUROCRINE BIOSCIENCES INC NBIX 5.2400%
NRX THERAPEUTICS INC NRXP 5.2100%
BRIGHT MINDS BIOSCIENCES INC DRUG 5.0500%
Top 10 Holdings Weight: 69.7%
Number of Holdings: 29
Shares Outstanding: 1,184,976
Total Net Assets: 21,376,970
NAV: 17.84
Net Expense Ratio: 1.00%
Asset Class: Equities (Stocks)
Developed or Emerging: Developed Market Funds
Country:
Region:
Strategy:
Currency:
Commodity:
Sector: Healthcare
Industry: Pharmaceuticals
Dividend Type:
Tax Exempt State:
Maturity Duration:
Market Cap: Broad Market / Multi-Cap
Credit Quality:
Mortgage Bond Types:
Bond Type:
Gov't Bond Types:
Reit Type:
Leverage Direction/Factor:
Is Currency Hedged: No
US or Ex-US: Global
Market Data Delayed 15 Minutes